Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 13/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930530 | 0.83 | AVPR2 (0.65) | AVPR2AVPR1ACTSS | |
| SCHEMBL2437361 | 0.81 | AVPR2 (0.53) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL6929190 | 0.79 | AVPR2 (0.57) | AVPR2AVPR1ANR1H2NR1H3 | |
| SCHEMBL6929566 | 0.75 | AVPR2 (0.53) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL6927611 | 0.75 | AVPR2 (0.63) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL2442420 | 0.74 | AVPR2 (0.56) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL2444177 | 0.74 | AVPR2 (0.62) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL6929253 | 0.74 | AVPR2 (0.49) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL6930488 | 0.73 | AVPR2 (0.80) | AVPR2AVPR1ADRD2DRD4DRD3 | |
| SCHEMBL6929760 | 0.73 | AVPR2 (0.68) | AVPR2AVPR1ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | AVPR2 3835/4885AVPR1A 3944/4885DRD2 2890/4885 |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | AVPR2 3835/4885AVPR1A 3944/4885DRD2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.